AMBIGUOUS RESULTS

Lantern Pharma's LP-184 hits 45% disease control rate in Phase 1a tumor trial

The 63-patient dose-escalation trial reported the disease control rate only among patients treated at or above the effective dose, with safety data still unreported.

Lantern Pharma completed a 63-patient Phase 1a trial of LP-184 in relapsed or refractory advanced solid tumors and reported a 45% disease control rate among patients dosed at or above the effective therapeutic dose.

By AppliedXLJuly 23, 2026Trial NCT05933265

Executive Summary

Lantern Pharma's Phase 1a trial of LP-184 in advanced tumors reported a 45% disease control rate in patients dosed at or above the drug's effective therapeutic level, giving the company its first disclosed efficacy signal for the asset.
The trial was designed to find a tolerable dose and characterize safety and pharmacokinetics, not to establish efficacy on a controlled comparison, so the reported rate is descriptive rather than a formal endpoint result.
Lantern is pairing the readout with a new patent covering a biomarker signature meant to select patients most likely to respond, tying the trial result directly to how the company plans to run its next studies.
LP-184's target sits in a field of one active industry trial, while the broader advanced-tumor landscape is dominated by unrelated, more mature mechanisms already in Phase 3 testing.

The readout

Lantern Pharma disclosed results from a completed 63-patient Phase 1a trial of LP-184, an acylfulvene prodrug, in patients with recurrent or refractory advanced tumors. Among patients dosed at or above the effective therapeutic dose, the disease control rate was 45%, the company said. Kishor Bhatia, Lantern's chief scientific officer, said the target enzyme PTGR1 "is associated with aggressive tumor biology, and it is the enzyme that activates LP-184 inside the tumor cell". The trial, registered as NCT05933265, lists enrollment of 64 patients and enrolled 63. Lantern+1

Probability of Success

Endpoint Met91%

Completes48%

Clinical Significance9%

Regulatory85%

What the trial was built to test

NCT05933265 is a non-randomized, open-label Phase 1/2 basket trial with three primary endpoints: the recommended Phase 2 dose, the maximum tolerated dose, and the incidence and severity of adverse events graded by CTCAE v5.0. Disease control and overall response rate sit among six secondary endpoints, evaluated by RECIST 1.1 or RANO 2.0 criteria depending on tumor type. That structure means the trial's central job was to characterize tolerability and find a workable dose across a mix of tumor types, including triple-negative breast cancer, non-small cell lung cancer, pancreatic adenocarcinoma, and glioma, with the disease-control figure arriving as a secondary, dose-restricted signal rather than the trial's primary readout. NCT05933265

Enrollment and timing history

The trial's registered enrollment moved several times over its life: from 35 to 30 patients in late 2023, up to 175 in January 2025, and back down to 64 in May 2026 when the trial's status shifted to Active, not recruiting. The primary completion date moved twice, from December 2024 to February 2025 and then to July 28, 2026. Lantern first flagged the possibility of an initial Phase 1a readout for the second half of 2024; the completed results arrived in July 2026, alongside the trial's near-final registered completion date. NCT05933265+2

Mechanism and selection strategy

LP-184 is a prodrug activated inside tumor cells by the enzyme PTGR1, forming a reactive metabolite that induces DNA cross-links and double-strand breaks in tumors with deficient DNA damage repair pathways. Lantern also disclosed that the U.S. Patent and Trademark Office issued a notice of allowance covering a biomarker signature, elevated expression of PTGR1, PTPN14, and ASPH, to select patients for LP-184 treatment in ovarian, liver, kidney, and thyroid cancers. The company said this selection approach is intended to increase the likelihood of response in future trials, and LP-184 is planned for multiple Phase 1b/2 precision-oncology trials during 2026. Lantern

Where LP-184 sits competitively

Only one active industry trial studies PTGR1 in advanced tumors, LP-184's own. The broader advanced-tumor field is populated by different, more advanced mechanisms: Merck's pembrolizumab and AstraZeneca's saruparib and trastuzumab deruxtecan programs are running in Phase 3 across various tumor types, none sharing LP-184's DNA-adduct-forming mechanism. With no other PTGR1-targeted program in active testing for this indication, the disease-control signal stands as an early, uncontested read on whether the mechanism produces tumor activity, a question the field's Phase 3 incumbents in checkpoint inhibition and antibody-drug conjugates have already answered for their own targets but not for this one. NCT05933265

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.